Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Genomics (NASDAQ:TXG – Free Report) had its price objective lowered by Canaccord Genuity Group from $20.00 to $18.00 in a ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...